By Clinical Informatics News Staff 

January 12, 2017 | Sarah Cannon today announced that Genospace will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.

Genospace, which will remain based in Cambridge, Mass., is leading the development and enhancement of a cloud-based system that enables analysis of disparate data from clinical and laboratory sources across patient populations.

Genospace launched Trial Match, a mobile app which enables real time clinical trial matching, in September of last year, which was covered by Clinical Informatics News.

Through the collaboration of Sarah Cannon and Genospace, the genomics data technology will be integrated into Sarah Cannon’s network of oncology programs across the United States and United Kingdom.

“As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making,” said Howard A. “Skip” Burris III, President, Clinical Operations and Chief Medical Officer, Sarah Cannon, in a statement. “Genospace’s leadership in this field will help us to transform the way we gather and analyze genomic information, resulting in better identification of effective treatment options for our patients.”

Terms of the agreement were not disclosed. Sarah Cannon expects to complete the transaction in the first quarter of this year.